TENX (STOCKS)
Tenax Therapeutics, Inc.
$13.000000
+0.210000 (+1.64%)
Prev close: $12.790000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Christopher T. Giordano
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $81.55M
- Employees
- 6
- P/E (TTM)
- -11.28
- P/B (TTM)
- 0.79
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.40 | $-0.32 | -0.0812 | -25.47% |
|
Jun 2025 (Q2)
|
$-0.27 | $-0.24 | -0.0252 | -10.29% |
|
Mar 2025 (Q1)
|
$-0.28 | $-0.20 | -0.0828 | -41.99% |
|
Dec 2024 (Q4)
|
$-0.18 | $-0.43 | +0.2510 | +58.24% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $47.23M |
| Research and Development | $26.73M |
| Other Operating Expenses | $20.51M |
| Operating Income/Loss | -$47.23M |
| Income/Loss From Continuing Operations After Tax | -$43.33M |
| Income/Loss From Continuing Operations Before Tax | -$43.33M |
| Net Income/Loss | -$43.33M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$43.33M |
| Net Income/Loss Available To Common Stockholders, Basic | -$43.33M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.74 |
| Diluted Earnings Per Share | -$0.74 |
| Basic Average Shares | 45,633,982 |
| Diluted Average Shares | 45,633,982 |
| Assets | $102.81M |
| Current Assets | $102.81M |
| Noncurrent Assets | $0.00 |
| Liabilities | $6.60M |
| Current Liabilities | $6.60M |
| Accounts Payable | $5.61M |
| Wages | $858.00K |
| Other Current Liabilities | $133.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $96.21M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $96.21M |
| Liabilities And Equity | $102.81M |
| Net Cash Flow From Operating Activities | -$25.91M |
| Net Cash Flow From Operating Activities, Continuing | -$25.91M |
| Net Cash Flow From Investing Activities | -$1.06M |
| Net Cash Flow From Investing Activities, Continuing | -$1.06M |
| Net Cash Flow From Financing Activities | $26.97M |
| Net Cash Flow From Financing Activities, Continuing | $26.97M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$43.33M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$43.33M |
| Other Comprehensive Income/Loss | $0.00 |